Judge Asks GSK To Tweak Details In $10.4M Paxil Settlement

Law360, Los Angeles (April 25, 2012, 9:52 PM EDT) -- GlaxoSmithKline Inc.'s proposal to pay up to $10.4 million to resolve allegations that it misled California consumers about the risks of antidepressant Paxil will need revisions to determine how class members will prove they're eligible for payments, a California judge told the drugmaker Wednesday.

Los Angeles Superior Court Judge Elihu M. Berle ordered attorneys for GSK and lead plaintiff Diana Hunter to discuss alternatives to the deal's payment provisions, which call for $8.5 million to go to class members who have documentary proof they purchased Paxil between January 1999 and January 2003, while setting aside only $500,000 for class members lacking...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!